Number of patients potentially eligible for proton therapy

Research output: Contribution to journalReview article

Standard

Number of patients potentially eligible for proton therapy. / Glimelius, B; Ask, Anders; Bjelkengren, Göran; Bjork-Eriksson, T; Blomquist, E; Johansson, B; Karlsson, M; Zackrisson, B.

In: Acta Oncologica, Vol. 44, No. 8, 2005, p. 836-849.

Research output: Contribution to journalReview article

Harvard

Glimelius, B, Ask, A, Bjelkengren, G, Bjork-Eriksson, T, Blomquist, E, Johansson, B, Karlsson, M & Zackrisson, B 2005, 'Number of patients potentially eligible for proton therapy', Acta Oncologica, vol. 44, no. 8, pp. 836-849. https://doi.org/10.1080/02841860500361049

APA

Glimelius, B., Ask, A., Bjelkengren, G., Bjork-Eriksson, T., Blomquist, E., Johansson, B., Karlsson, M., & Zackrisson, B. (2005). Number of patients potentially eligible for proton therapy. Acta Oncologica, 44(8), 836-849. https://doi.org/10.1080/02841860500361049

CBE

Glimelius B, Ask A, Bjelkengren G, Bjork-Eriksson T, Blomquist E, Johansson B, Karlsson M, Zackrisson B. 2005. Number of patients potentially eligible for proton therapy. Acta Oncologica. 44(8):836-849. https://doi.org/10.1080/02841860500361049

MLA

Vancouver

Glimelius B, Ask A, Bjelkengren G, Bjork-Eriksson T, Blomquist E, Johansson B et al. Number of patients potentially eligible for proton therapy. Acta Oncologica. 2005;44(8):836-849. https://doi.org/10.1080/02841860500361049

Author

Glimelius, B ; Ask, Anders ; Bjelkengren, Göran ; Bjork-Eriksson, T ; Blomquist, E ; Johansson, B ; Karlsson, M ; Zackrisson, B. / Number of patients potentially eligible for proton therapy. In: Acta Oncologica. 2005 ; Vol. 44, No. 8. pp. 836-849.

RIS

TY - JOUR

T1 - Number of patients potentially eligible for proton therapy

AU - Glimelius, B

AU - Ask, Anders

AU - Bjelkengren, Göran

AU - Bjork-Eriksson, T

AU - Blomquist, E

AU - Johansson, B

AU - Karlsson, M

AU - Zackrisson, B

PY - 2005

Y1 - 2005

N2 - A group of Swedish radiation oncologists and hospital physicists have estimated the number of patients in Sweden suitable for proton beam therapy in a facility where one of the principal aims is to facilitate randomized and other studies in which the advantage of protons can be shown and the magnitude of the differences compared with optimally administered conventional radiation treatment, also including intensity-modulated radiation therapy (IMRT) and brachytherapy, can be shown. The estimations have been based on current statistics of tumour incidence in Sweden, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours together with information on normal tissue complication rates. In Sweden, it is assessed that between 2200 and 2500 patients annually are eligible for proton beam therapy, and that for these patients the potential therapeutic benefit is so great as to justify the additional expense of proton therapy. This constitutes between 14- 15% of all irradiated patients annually.

AB - A group of Swedish radiation oncologists and hospital physicists have estimated the number of patients in Sweden suitable for proton beam therapy in a facility where one of the principal aims is to facilitate randomized and other studies in which the advantage of protons can be shown and the magnitude of the differences compared with optimally administered conventional radiation treatment, also including intensity-modulated radiation therapy (IMRT) and brachytherapy, can be shown. The estimations have been based on current statistics of tumour incidence in Sweden, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours together with information on normal tissue complication rates. In Sweden, it is assessed that between 2200 and 2500 patients annually are eligible for proton beam therapy, and that for these patients the potential therapeutic benefit is so great as to justify the additional expense of proton therapy. This constitutes between 14- 15% of all irradiated patients annually.

U2 - 10.1080/02841860500361049

DO - 10.1080/02841860500361049

M3 - Review article

VL - 44

SP - 836

EP - 849

JO - Acta Oncologica

JF - Acta Oncologica

SN - 1651-226X

IS - 8

ER -